Gitnux/Report 2026

Pharmaceutical Wholesale Industry Statistics

281Statistics
73Sources
12Sections
1Visuals
46mRead
Pharmaceutical Wholesale Industry Statistics
Samuel NorbergWritten by Samuel Norberg·Fact-checked by Maya Johansson
Published
How this report is researched
01Editorial Scope

Before any source is gathered, an editor locks the question, what qualifies, and how the piece will be judged.

02Source Research

Search agents collect the source set and pull each data point out with its provenance attached.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 39 days

01 Industry overview

The pharmaceutical wholesale industry at a glance

U.S. traditional pharmaceutical distributor sales reached $969 billion in 2025, growing 11.6% as specialty medicines expanded and distributors continued to handle most prescription-drug sales.

$969B[1]
U.S. distributor sales, 2025
11.6%[1]
Distributor sales growth, 2025
40.5%[1]
Specialty branded sales share, 2025
85%[57]
Top three U.S. wholesaler share, 2024
Market size
Traditional pharmaceutical distributor sales in the United States reached $969 billion in 2025. The sector represented the principal channel for prescription medicines, with distributor sales accounting for 96% of prescription-drug sales in 2024.[1]
Forecast & CAGR
The global pharmaceuticals wholesale and distribution market is forecast to expand by approximately $1.097 trillion from 2025 to 2030, representing a 9.7% CAGR. This estimate covers wholesale distribution and related pharmaceutical supply-chain activities across major regions.[62]
Market share & regions
North America was forecast to contribute nearly 48% of global incremental market growth between 2025 and 2030, supported by its established pharmaceutical logistics infrastructure. In the broader pharmaceutical market, North America represented 45% of global consumption by value in 2024, compared with approximately 26% for Europe.[62][63]
Segmentation
In U.S. distributor sales in 2025, brand-name prescription drugs represented 51.1% of sales, specialty branded prescription drugs 40.5%, and generic drugs 5.4%. By customer type, chain drug stores accounted for 44.5%, specialty pharmacies 7.4%, independent drug stores 10.6%, and hospitals and HMOs 12.7%.[1]
Key players & concentration
The U.S. wholesale market is highly concentrated among McKesson, Cencora, and Cardinal Health. Pfizer reported that these three wholesalers represented 34%, 29%, and 22%, respectively, of its U.S. gross revenue in 2024, or 85% combined.[57]
Pricing
Distributor economics remain low-margin despite very large sales volumes: the HDA Research Foundation reported a 0.48% net profit margin for traditional pharmaceutical distributors in 2025. The margin was 0.20% in 2024, indicating continued pressure from operating costs, reimbursement arrangements, and competitive pricing.[1]
Trends, drivers & challenges
Growth is being driven by higher prescription volumes and specialty medicines: specialty branded products increased to 40.5% of distributor sales in 2025 from 38.5% in 2024. Key challenges include supply interruptions, narrow margins, complex reimbursement terms, counterfeit and diversion risks, and the cost of implementing electronic package-level traceability.[1][64]
Consumer behavior & competition
Purchasing is shifting toward chain drug stores and specialty pharmacies: chain stores rose to 44.5% of distributor sales in 2025 from 40.5% in 2024, while specialty pharmacies increased to 7.4% from 6.4%. Competition includes national full-line wholesalers, regional and specialty distributors, manufacturer-direct channels, third-party logistics providers, and large payer organizations.[1][57]
M&A
M&A is supporting vertical integration and specialty-distribution expansion. McKesson reported that it completed the sale of its retail and distribution businesses in Norway on January 30, 2026, while its fiscal 2026 oncology and multispecialty revenue grew 31% to $48.4 billion, including contributions from acquisitions.[57]
Regulation
In the United States, the Drug Supply Chain Security Act requires wholesale distributors and third-party logistics providers to maintain appropriate licenses and report licensure information annually to the FDA. Enhanced requirements target interoperable electronic tracing of certain prescription drugs at the package level, while FDA exemptions for some small-business dispensers extend to November 27, 2027.[64]
Latest news
The latest HDA Factbook, released September 24, 2026, reported that U.S. traditional pharmaceutical distributor sales grew 11.6% to $969 billion in 2025. It also reported average inventory of approximately $55 billion, 22 days of inventory on hand, and capital expenditure of $685 million.[1]

02 Ranking

Top 10 Companies in the Pharmaceutical Wholesale Industry

The leading companies in the pharmaceutical wholesale industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 10, 2026 · Next review December 10, 2026

Verdict

McKesson leads Gitnux's 2026 pharmaceutical wholesale ranking with an Overall score of 9.5, with revenue growth 16.2% and operating margin 1.2%. Cencora is the runner-up at 9.2, with revenue growth 9.3% and operating margin 0.8%.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in pharmaceutical distribution

    McKesson

    US

    Ranked #1 · 9.5 · Pharmaceutical distribution

    Why we picked it: It distributes medicines daily to pharmacies, hospitals, and health systems in North America and reports 16.2% revenue growth.

    See in ranking ↓Visit mckesson.com ↗

  2. #2 overall

    Cencora

    US

    Ranked #2 · 9.2 · Pharmaceutical distribution

    Why we picked it: It serves pharmacies and health systems through a global distribution network and reports 9.3% revenue growth.

    See in ranking ↓Visit cencora.com ↗

  3. #3 overall

    Cardinal Health

    US

    Ranked #3 · 8.7 · Pharmaceutical distribution

    Why we picked it: It distributes pharmaceuticals and serves healthcare providers globally, with -1.9% revenue growth reported.

    See in ranking ↓Visit cardinalhealth.com ↗

Pick 1 is the #1 company overall. No other segment places in the top 5, so picks 2 and 3 follow rank.

Full ranking

Sort by
Top 10 companies in the pharmaceutical wholesale industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

McKesson

Pharmaceutical distribution · US

9.5
2

Cencora

Pharmaceutical distribution · US

9.2
3

Cardinal Health

Pharmaceutical distribution · US

8.7
4

Zuellig Pharma

Pharmaceutical distribution · SG

8.7
5

PHOENIX group

Pharmaceutical distribution · DE

8.5
6

DKSH

Healthcare distribution, Asia-Pacific · CH

8.4
7

Sinopharm Group

Pharmaceutical distribution, China · CN

8.1
8

Alfresa Holdings

Pharmaceutical wholesaling, Japan · JP

8.0
9

China Resources Pharmaceutical Group

Pharmaceutical distribution, China · CN

7.9
10

Toho Holdings

Pharmaceutical wholesaling, Japan · JP

7.8

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 10, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 10). Top 10 companies in the pharmaceutical wholesale industry. In Pharmaceutical Wholesale Industry Statistics. Gitnux. https://gitnux.org/pharmaceutical-wholesale-industry-statistics/#top-companies

report visual · Projection

Sectoral output of drugs and druggists’ sundries merchant wholesalers (United States)

Sectoral output of drugs and druggists’ sundries merchant wholesalers grew from 420,925.5 millions of USD in 2021 to 564,209.9 millions of USD in 2025.

$420.9K
Start
+7.6%
CAGR · 4y
$564.2K
Projected
20212025
source-verifiedfred.stlouisfed.org2025

04 Statistics

Technology & Innovation

Respondents point to AI use for cost and exception handling: 89% expect AI can reduce distribution costs. Center throughput data also supports automation (e.g., 50% automated invoice picks in 2024).

AI in the pharmaceutical wholesale industry

  • 76% of surveyed pharmaceutical-distributor respondents say AI could be effective or very effective in addressing returns and waste, survey year not stated.[1]
  • 17% of surveyed pharmaceutical-distributor respondents currently use AI for supply-chain safety, security and integrity, survey year not stated.[1]
  • 78% of surveyed pharmaceutical-distributor respondents who identify storage and handling as pain points express confidence that AI can address them, survey year not stated.[1]
  • 8% of surveyed pharmaceutical-distributor respondents currently use AI for disaster preparedness and addressing drug shortages, survey year not stated.[1]
  • 33% of surveyed pharmaceutical-distributor respondents expect AI to be somewhat effective in overcoming internal data limitations, survey year not stated.[1]
  • 89% of surveyed pharmaceutical-distributor respondents expect AI to be effective or very effective at reducing distribution costs, survey year not stated.[1]

Automation in the pharmaceutical wholesale industry

  • 9% of global pharmaceutical supply-chain respondents rated simulation of automated and manual processes very important or important in 2024.[2]
  • 11% of global pharmaceutical supply-chain respondents rated direct delivery to patients, clinics or hospitals very important or important in 2024.[2]
  • Approximately 102,000 units were processed daily by the average U.S. traditional pharmaceutical-distribution center in 2025.[1]
  • 26% of global pharmaceutical supply-chain respondents rated automation and robotics in distribution centers very important or important in 2024.[2]
  • 8% of global pharmaceutical supply-chain respondents rated inbound optimization very important or important in 2024.[2]
  • 50% of invoice lines at U.S. pharmaceutical distributors were picked through automated processes in 2024.[1]

Digital Transformation in the retail and e-commerce sector (sector benchmark)

  • Among EU small and medium-sized enterprises, 71% reached at least a basic level of digital intensity in 2025.[3]
  • Across retail and consumer-goods companies, 70% of business functions had generative AI adopted or piloted in 2025.[4]
  • Across EU businesses, 74% reached at least a basic level of digital intensity in 2024.[3]
  • Among EU large businesses, 96% reached at least a basic level of digital intensity in 2025.[3]

Technology Adoption in the retail and e-commerce sector (sector benchmark)

  • Across US and European retailers, 16% had fully scaled artificial intelligence in 2025.[5]
  • Across US and European retailers, 23% had fully scaled wireless communication technologies such as RFID or Bluetooth in 2025.[5]
  • Across US and European retailers, 27% had fully scaled cameras and sensors in 2025.[5]
  • Across US and European retailers, 21% had fully scaled edge computing technologies in 2025.[5]
  • Across US and European retailers, 66% had moved beyond exploration and testing of store-intelligence technologies in 2025.[5]

Cloud Computing in the retail and e-commerce sector (sector benchmark)

  • Across EU enterprises using paid cloud services, 45.52% hosted enterprise databases in the cloud in 2025.[3]
  • Across EU enterprises using paid cloud services, 71.69% used cloud-based office software in 2025.[3]
  • Across EU enterprises using paid cloud services, 71.53% used cloud-based file storage in 2025.[3]
  • Across EU enterprises using paid cloud services, 85.15% used cloud-based email in 2025.[3]
  • Across EU enterprises, 52.74% used paid cloud-computing services in 2025.[3]

Big Data in the retail and e-commerce sector (sector benchmark)

  • Across retail companies, 64% said their customer data was structured and accessible enough to support artificial-intelligence use cases in 2025.[6]
  • Across EU enterprises, 33.02% performed data analytics using their own employees in 2025.[3]
  • Across retail companies, 23% were using artificial intelligence in production to resolve customer identities or prepare customer data for marketing or analytics in 2025.[6]
  • Across EU enterprises, 26.20% performed data analytics on transaction records such as sales and payment records in 2025.[3]

05 Statistics

Data & Analytics

Operational visibility shows up as measurable network activity, including 108 million annual deliveries through Cencora’s U.S. distribution network. Fill-rate and invoice performance metrics tie analytics to execution.

Business intelligence in the pharmaceutical wholesale industry

  • $386 million was invested in healthcare-distributor capital expenditures in 2024, including spending on information technology and operational infrastructure.[1]
  • 5.8 million square feet of warehouse space supports Cencora’s U.S. pharmaceutical distribution network, providing the operating footprint for digital visibility and reporting.[7]
  • 108 million annual deliveries and shipments are handled through Cencora’s U.S. pharmaceutical distribution network, according to the company’s current network overview.[7]
  • 12% was Cencora specialty distribution sales growth in 2024, while the company described real-time data as supporting supply-chain decision-making.[7]
  • Nearly 4,900 orders were processed each day by Cencora specialty distributors in 2024, a workload for which the company cites AI and advanced analytics as enabling technologies.[7]
  • 99.77% was Cencora’s on-time shipping performance, according to its pharmaceutical distribution excellence overview.[7]

Data analytics in the pharmaceutical wholesale industry

  • 4,132 orders were processed on an average business day by each traditional pharmaceutical-distribution center in 2024.[1]
  • 89% of raw-order invoice lines were filled by traditional pharmaceutical distributors in 2024, up from 88% in 2023 and 86% in 2022.[1]
  • 200% is the planned increase in frozen storage capacity in Cencora’s Dothan, Alabama expansion for specialty-pharmaceutical distribution.[7]
  • 70% of unfilled pharmaceutical-distributor invoice lines in 2024 were attributed to manufacturers’ inability to ship, while 30% were attributed to distributor stockouts.[1]
  • 68% of pharmaceutical-distribution companies reported using automated methods in 2024, according to the HDA Factbook.[1]
  • 500% is the planned increase in refrigerated storage capacity in Cencora’s Dothan, Alabama expansion, supported by digitalized pharmaceutical distribution operations.[7]

Data Quality in the retail and e-commerce sector (sector benchmark)

  • Across retail and e-commerce, 66% of respondents identified data-quality controls as a significant challenge in 2024.[8]
  • Across retail and e-commerce, 48% of respondents rated their customer-data collection methods only somewhat effective in 2024.[8]
  • Across retail and e-commerce, 29% of respondents rated their customer-data collection methods not very effective in 2024.[8]
  • Across retail and e-commerce, 62% of respondents rated their data-management practices only somewhat effective in 2024.[8]
  • Across retail and e-commerce, 66% of respondents rated their identity-resolution ability only somewhat effective in 2024.[8]

Data Governance in the retail and e-commerce sector (sector benchmark)

  • Across retail and consumer-products companies, 53.5% of respondents said regulatory compliance was not a significant data challenge in 2025.[9]
  • Across retail and consumer-products companies, 66% of respondents said their data-management capabilities were only somewhat unified in 2025.[9]
  • Across retail and CPG companies, 31% of respondents cited the lack of a corporate data strategy and semantic layer as a key challenge in 2025.[10]
  • Across retail and consumer-products companies, 96% of respondents said breaking down data silos was a significant challenge in 2025.[9]
  • Across retail and e-commerce, 57% of respondents identified data governance as a significant challenge in 2024.[8]
  • Across retail and CPG companies, 35% of respondents cited inconsistent or incorrect answers to data questions as a governance-related blocker in 2025.[10]

KPIs in the pharmaceutical wholesale industry

  • 6.2 times was the healthcare-distribution industry’s asset-turnover rate in 2024, up from 6.1 times in 2023.[1]
  • 6.4% of traditional pharmaceutical-distributor sales went to specialty pharmacies in 2024, up from 5.2% in 2023.[1]
  • 19 days was the average receivables period for healthcare distributors in 2024, down from 21 days in 2023.[1]
  • 11.7% of traditional pharmaceutical-distributor sales went to independent pharmacies in 2024, down from 13.1% in 2023.[1]
  • $862 billion was pharmaceutical-distributor sales in 2024, representing 96% of all U.S. prescription-drug sales tracked by HDA.[1]
  • 15.9% of traditional pharmaceutical-distributor sales went to hospitals, HMOs and clinics in 2024.[1]

06 Statistics

Strategy & Growth

Growth and investment coexist with narrow economics: U.S. distributor sales grew 11.6% in 2025, while the HDA Research Foundation reported 0.48% net profit margin in 2025.

Growth in the pharmaceutical wholesale industry

  • 31% was McKesson’s fiscal-2026 full-year revenue growth in Oncology & Multispecialty.[11]
  • $49.0 billion was McKesson’s fiscal-2025 year-over-year increase in pharmaceutical revenue.[12]
  • 18% was McKesson’s fiscal-2025 increase in pharmaceutical revenue compared with the prior year.[12]
  • $776 billion was the projected 2024 drug-distribution revenue of Cencora, Cardinal Health and McKesson combined.[13]
  • $862 billion was the value of U.S. pharmaceutical distributor sales in 2024.[1]
  • 11% was McKesson’s fiscal-2026 full-year revenue growth in North American Pharmaceutical.[11]

Differentiation in the pharmaceutical wholesale industry

  • 200% is the planned increase in frozen storage capacity at Cencora’s Dothan, Alabama facility.[7]
  • 0.2% was the average after-tax net margin of pharmaceutical distributors in 2024.[1]
  • 52% of U.S. pharmaceutical distributor dollar sales were branded non-specialty products in 2024.[1]
  • 500% is the planned increase in refrigerated storage capacity at Cencora’s Dothan, Alabama facility.[7]
  • 140 logistics sites across more than 50 countries support Cencora’s global specialty-logistics operations.[7]
  • 130 strategically located distribution centers were operated by HDA members in 2024.[1]

Mergers and acquisitions in the pharmaceutical wholesale industry

  • 13% was Apollo Funds’ approximate minority ownership interest in McKesson’s Medical-Surgical Solutions business.[11]
  • 85% was Cencora’s ownership stake in Retina Consultants of America after the 2025 acquisition.[14]
  • $1.9 billion was the announced cash purchase price for Cardinal Health’s acquisition of Solaris Health.[15]
  • $1.1 billion was Cardinal Health’s announced cash purchase price for Advanced Diabetes Supply Group.[16]
  • $13 billion was the approximate enterprise value assigned to McKesson’s Medical-Surgical Solutions business in the Apollo transaction.[11]
  • $4.4 billion was Cencora’s cash outlay for approximately 85% of Retina Consultants of America in January 2025.[14]

Strategic partnerships in the pharmaceutical wholesale industry

  • 95 infusion centers were supported by GI Alliance’s affiliated physician network when Cardinal Health announced its transaction.[16]
  • 345 practice locations were included in GI Alliance’s platform across 20 states when Cardinal Health announced the transaction.[16]
  • 725 providers were added to McKesson’s US Oncology Network over the three fiscal years through 2025.[17]
  • 3 business channels—mail-order and specialty pharmacies, retail pharmacies, and distribution centers—are covered by McKesson’s CVS Health agreement.[17]
  • $41 billion was McKesson’s fiscal-2025 GLP-1 revenue, up 41% from fiscal 2024, reflecting demand across its pharmaceutical network.[17]
  • 135 ambulatory surgical centers were served by GI Alliance-affiliated doctors at the time of Cardinal Health’s strategic transaction.[16]

07 Statistics

People & Workforce

Workforce scale remains substantial even as operating models shift: U.S. healthcare distributors employed nearly 60,000 workers in 2023. Turnover, salary increase expectations, and training transition planning are quantified.

Hiring in the pharmaceutical wholesale industry

  • U.S. healthcare distributors employed nearly 60,000 workers in 2023.[1]
  • Walgreens Boots Alliance’s pharmaceutical-wholesale workforce increased from 27,000 employees in fiscal 2018 to 28,000 in fiscal 2019.[18]
  • Cencora reported full staffing across its U.S. distribution-center system at the end of fiscal 2024.[19]
  • U.S. healthcare distributors supported nearly 340,000 jobs in 2023 through direct and wider economic activity.[1]
  • More than 5,700 people joined Cencora in fiscal 2024, expanding its global pharmaceutical distribution workforce.[19]

Employee retention in the pharmaceutical wholesale industry

  • Cencora’s overall global employee turnover rate was approximately 23% in fiscal 2024, down from 30% in fiscal 2023.[19]
  • Healthcare distributors generally provided 3.5% salary increases in 2024.[1]
  • Healthcare distributors expected average salary increases of 3% for 2025.[1]
  • Healthcare-distributor payroll costs reached 17.4% of gross margin in 2024, compared with 14.1% in 2019.[1]
  • Cencora’s global voluntary turnover rate was 17% in fiscal 2024, down from 21% in fiscal 2023.[19]

Remote Work in the retail and e-commerce sector (sector benchmark)

  • Across U.S. retail trade, employees worked from home for 14.02% of full paid working days in 2025.[20]
  • Across U.S. retail trade, employees worked from home for 15.14% of full paid working days in 2022.[20]
  • Across U.S. retail trade, employees worked from home for 14.09% of full paid working days in 2026.[20]
  • Across U.S. retail trade, employees worked from home for 14.03% of full paid working days in 2023.[20]
  • Across U.S. retail trade, employees worked from home for 13.46% of full paid working days in 2024.[20]

Hybrid Work in the retail and e-commerce sector (sector benchmark)

  • Across U.K. employers, 74% had hybrid working in place in 2025.[21]
  • Across U.K. employers, 23% used informal manager-employee arrangements for hybrid work in 2025.[21]
  • Across U.K. employers, 42% had a formal hybrid-working policy in 2025.[21]
  • Across retail organizations globally, 42% used mandated office days as their hybrid-work model in 2025.[22]
  • Across U.K. employers, 65% required hybrid employees to attend the workplace a minimum number of days in 2025.[21]

Upskilling in the pharmaceutical wholesale industry

  • Cardinal Health required mental-health training for all bonus-eligible employees in fiscal 2025.[16]
  • Two ChemSkills organizations allocated between 20 and 80 learning hours per employee per year.[23]
  • 60% of ChemSkills respondents said their organization or department already offered training for the pharmaceutical industry transition.[23]
  • 10% of ChemSkills respondents said their organization planned to introduce pharmaceutical-transition training.[23]
  • 42% of surveyed pharmaceutical supply-chain organizations were adjusting or planning to adjust roles and career paths.[24]

Employee Engagement in the retail and e-commerce sector (sector benchmark)

  • Across U.S. retail workers, 24% reported one or more symptoms of burnout in Seramount’s spring 2025 survey.[25]
  • Across retail employees, 84% would recommend their company as a great place to work in Culture Amp’s 2024 dataset.[25]
  • Across retail employees, 71% agreed their company contributed to their learning and development in Culture Amp’s 2024 dataset.[25]
  • Across U.S. retail workers, 35% rated their personal well-being above average in Seramount’s spring 2025 survey.[25]
  • Across retail employees in Culture Amp’s 2024 dataset, 70% were engaged in 2025 reporting.[25]

08 Statistics

Customer & Sales

Customer mix continues to shift toward chain and specialty pharmacies, with 44.5% of distributor sales going to chain drug stores in 2025 and 7.4% to specialty pharmacies.

Customer experience in the pharmaceutical wholesale industry

  • 75% of Italian pharmacists obtained innovative medicines from pharmaceutical full-line wholesalers in 2016.[26]
  • 77% of French pharmacists obtained innovative medicines from pharmaceutical full-line wholesalers in 2016.[26]
  • 52% of French pharmacists obtained generic medicines from pharmaceutical full-line wholesalers in 2016.[26]
  • 98% of Italian pharmacists were satisfied with the full-line wholesale distribution system in 2016.[26]
  • 70% of French pharmacists obtained other branded medicines from pharmaceutical full-line wholesalers in 2016.[26]

09 Statistics

Marketing & Brand

Brand and pharmacy-audience reach is measured through communications volume, including 97,000+ pharmacy users reached through McKesson Connect in reported campaigns.

Marketing in the pharmaceutical wholesale industry

  • 91.2% of invoice lines were filled for raw orders by U.S. pharmaceutical distributors in 2025.[1]
  • 97,000+ pharmacy users were reached through McKesson Connect product-awareness communications.[11]
  • 22 days was the average inventory level held by U.S. pharmaceutical distributors in 2025.[1]
  • 88% of unfilled invoice lines were attributed to manufacturers’ inability to ship in 2025.[1]
  • 44.5% of distributor sales went to chain drug stores in 2025.[1]

Digital marketing in the pharmaceutical wholesale industry

  • 4,850 orders were processed by a typical U.S. specialty-distribution facility on an average business day in 2024.[1]
  • 200,000+ average monthly impressions were generated by McKesson product-awareness campaigns.[11]
  • 20,000+ monthly customer calls were processed by Pharmsource as an input for machine-learning analysis of drug names, pricing and market sentiment.[1]
  • 97,000+ pharmacy users were reached through McKesson Connect digital product communications.[11]
  • 5,000+ Health Mart stores received educational materials through McKesson’s pharmacy marketing services.[11]

Branding in the pharmaceutical wholesale industry

  • 5,000+ independent Health Mart pharmacies were supplied with educational materials supporting branded and specialty products.[11]
  • 38% of U.S. pharmaceutical distributor prescription sales comprised branded specialty drugs in 2023.[1]
  • 200,000+ average monthly impressions were delivered by McKesson campaigns supporting pharmaceutical brand communication.[11]
  • 97,000+ pharmacy users were included in McKesson’s branded-product communication audience across pharmacy segments.[11]
  • 53% of U.S. pharmaceutical distributor prescription sales comprised brand-name drugs in 2023.[1]

Social media in the pharmaceutical wholesale industry

  • 9,000+ LinkedIn followers were reported for Tamro Baltics, a pharmaceutical wholesaler operating in the Baltic region.[27]
  • 3.9 times higher LinkedIn engagement was reported for Tamro Baltics than for its main competitor.[27]

Influencer Marketing in the retail and e-commerce sector (sector benchmark)

  • 78% of surveyed brands reported growing creator-marketing budgets in 2025, up from 36% reporting budget growth in 2024.[28]
  • 80% of brands investing in creator marketing increased creator budgets in 2026, while 25% raised creator spending by more than 10%.[28]
  • 49% of brands investing in creator marketing reported sales as an impact of creator activity in 2026, compared with 60% citing brand sentiment and 58% citing awareness.[28]
  • 91% of brands investing in creator marketing ran an always-on component in 2026, including 62% with hybrid programs and 29% with fully continuous programs.[28]
  • 58% of brands integrated retail media networks and creator marketing platforms by amplifying creator-generated content on retail media channels in 2025.[28]

10 Statistics

Operations & Execution

Execution metrics show high operational tempo and low margin sensitivity. U.S. distributors held 22 days of inventory on hand in 2025, while net profit margin was 0.48%.

Process optimization in the pharmaceutical wholesale industry

  • 23 distribution centers enabled MWI Animal Health, AmerisourceBergen’s pharmaceutical-related distribution business, to move 100,000 lines per day.[29]
  • 20,000 packages per day were delivered by MWI Animal Health across its 23 distribution centers.[29]
  • 1,000 operational associates at MWI Animal Health supported the movement of 100,000 lines per day across 23 distribution centers.[29]
  • 44% of U.S. pharmaceutical distributors’ 2025 capital expenditures went to land, buildings, vehicles and other expenditures.[1]
  • 1.2 million line-haul miles were reduced by Cardinal Health’s pharmaceutical distribution bag-shipping initiative in fiscal 2025.[30]

Operational efficiency in the pharmaceutical wholesale industry

  • 0.48% was the net profit margin reported by U.S. traditional pharmaceutical distributors in 2025.[1]
  • 54.6 days was the average accounts-payable period for U.S. pharmaceutical distributors in 2024.[1]
  • 22 days was the average inventory on hand for U.S. traditional pharmaceutical distributors in 2025.[1]
  • 19.4 days was the average receivables-collection period for U.S. pharmaceutical distributors in 2024.[1]
  • $91,000 was the average employee compensation at U.S. pharmaceutical distributors in 2025.[1]

Quality management in the pharmaceutical wholesale industry

  • 32% of surveyed pharmaceutical distributors met the GDP-level threshold for self-inspection.[31]
  • 32% of surveyed pharmaceutical distributors met the GDP-level threshold for dispatch procedures.[31]
  • 16% of surveyed pharmaceutical distributors met the GDP-level threshold for physical storage conditions.[31]
  • 41% of surveyed pharmaceutical distributors met the GDP-level threshold for warehouse organization.[31]
  • 22% of surveyed pharmaceutical distributors in low- and middle-income countries met the study’s GDP-level threshold for a quality-assurance system.[31]

Supply chain in the pharmaceutical wholesale industry

  • 63% of surveyed manufacturers wanted European full-line wholesalers to improve order quantity.[26]
  • 81% of surveyed manufacturers wanted European full-line wholesalers to improve stock-level transparency.[26]
  • 62% of surveyed manufacturers wanted European full-line wholesalers to improve their order systems.[26]
  • 16.02 deliveries per week was the average frequency reported for European full-line pharmaceutical wholesalers in the 2016 manufacturer survey.[26]
  • 4,900 specialty-pharmaceutical distribution orders were processed each day in 2024.[7]

Outsourcing / Offshoring in the retail and e-commerce sector (sector benchmark)

  • 72% of retail organizations with $100 million–$150 million in revenue outsourced some or all fulfillment in 2025.[32]
  • 57% of retail organizations with $50 million–$100 million in revenue outsourced some or all fulfillment in 2025.[32]
  • 74% of retailers surveyed sourced internationally, including 71% of small companies and 84% of larger companies, in 2024.[33]
  • 76% of retail organizations with $150 million–$200 million in revenue outsourced some or all fulfillment in 2025.[32]
  • Among U.S. apparel imports, China’s share fell from 30% in 2019 to 21% in 2023, while other Asian suppliers’ share rose from 30% to 35%.[34]

11 Statistics

Finance & Pricing

Economics remain compressed: HDA Research Foundation reported a 0.48% net profit margin in 2025, and specialty branded share rose to 40.5% of distributor sales in 2025.

Pricing strategy in the pharmaceutical wholesale industry

  • 4.1% was the 2022 median margin percentage for U.S. wholesalers on brand drugs sold through retail channels.[35]
  • $8 billion was the modeled 2023 reduction in U.S. wholesaler gross revenue from switching to a 3% markup on net prices.[36]
  • $24.3 was the 2022 median net margin per package for U.S. wholesalers on brand drugs sold through retail channels.[35]
  • 3% was the illustrative wholesaler markup on net prices modeled in a 2023 U.S. pharmaceutical distribution analysis.[36]
  • $655.1 was the 2022 median sales price per package for brand drugs sold by U.S. wholesalers through retail channels.[35]

Cost reduction in the pharmaceutical wholesale industry

  • 15.5% was the increase in U.S. traditional pharmaceutical-distributor sales in 2022.[1]
  • 13.7% was the increase in U.S. traditional pharmaceutical-distributor sales in 2023.[1]
  • 7.4% of U.S. traditional-distributor sales went to specialty pharmacies in 2025.[1]
  • 11.6% was the increase in U.S. traditional pharmaceutical-distributor sales in 2025.[1]
  • $969 billion was U.S. traditional pharmaceutical-distributor sales in 2025.[1]

Profitability in the pharmaceutical wholesale industry

  • 6.3% was the 2022 margin percentage for U.S. wholesalers across all drugs sold through retail channels.[37]
  • $23.4 billion was the aggregate 2022 margin earned by U.S. wholesalers across retail-channel drug sales.[37]
  • 1.04% was the preliminary operating margin reported by Japanese pharmaceutical-wholesaler members in fiscal 2025.[38]
  • 1.7% was the weighted-average pretax profit margin for U.S. pharmaceutical-distributor sales in 2023.[1]
  • 1.11% was the operating margin reported by Japanese pharmaceutical-wholesaler members in fiscal 2024.[38]

Financial planning in the pharmaceutical wholesale industry

  • $623.9 billion was U.S. pharmaceutical-distribution sales to chain drug stores, hospitals and other customers in 2023 in the HDA reporting set.[1]
  • $938.3 million was 2025 gross profit in the Pharmacy Solutions segment in that U.S. pharmaceutical-distribution filing.[39]
  • $862 billion was U.S. traditional pharmaceutical-distributor sales in 2024, representing 96% of prescription-drug sales.[1]
  • 40.5% of U.S. traditional-distributor sales came from specialty branded prescription drugs in 2025.[1]
  • 13.5% was the increase in the HDA reporting set’s U.S. pharmaceutical-distribution sales from 2022 to 2023.[1]

12 Statistics

Product & Service

Product mix is quantified alongside returns handling: 51.1% of 2025 U.S. distributor sales were brand-name prescription drugs and 2.34% was the unsaleable-return rate.

Product development in the pharmaceutical wholesale industry

  • 40 local, regional and national distributors were HDA members in 2024.[1]
  • 31% of U.S. healthcare-distributor capital expenditures went to information technology in 2024.[1]
  • 96% of U.S. pharmaceutical sales went through distributors in 2024, supporting broad market introduction of medicines.[1]
  • 130 strategically located distribution centers were operated by HDA-member distributors in 2024.[1]
  • $862 billion in U.S. pharmaceutical sales passed through distributors in 2024.[1]

Product lifecycle in the pharmaceutical wholesale industry

  • 30 days was the typical inventory holding period for generic products at U.S. healthcare distributors in 2024.[1]
  • 2.68% of pharmaceutical returns were classified as unsaleable in 2025.[40]
  • 51.1% of U.S. pharmaceutical-distributor sales were brand-name prescription drugs in 2025.[1]
  • 2.34% was the unsaleable-return rate for retail pharmaceutical products in 2025.[40]
  • 5.4% of U.S. pharmaceutical-distributor sales were generic drugs in 2025.[1]

After-sales in the pharmaceutical wholesale industry

  • 99.77% was Cencora’s on-time shipping performance for pharmaceutical distribution operations.[7]
  • 4,600 orders were processed daily by the average traditional U.S. pharmaceutical distribution center in 2025.[12]
  • 4,850 orders were processed by a typical HDA-member specialty distribution facility, with orders delivered to providers within one day in 2024.[1]
  • 99.1% was the fill rate reported for a typical HDA-member specialty distribution facility in 2024.[1]
  • 22 units was the average number of pharmaceutical products per distributor order in 2024.[7]

Value proposition in the pharmaceutical wholesale industry

  • More than 90% of U.S. wholesale drug distribution was accounted for by Cencora, Cardinal Health and McKesson in 2022.[41]
  • 20.4% of pharmaceutical-distribution industry sales came from hospitals, HMOs and clinics in 2023.[1]
  • Less than 1% of the cost of brand medicines was the estimated cost of distributor delivery services in a 2025 HDA analysis.[1]
  • $33 billion to $53 billion per year was the estimated healthcare-system saving generated by U.S. pharmaceutical distributors.[1]
  • 6.3% was the estimated gross margin of U.S. wholesalers in 2022.[35]

13 Statistics

Sustainability & Ethics

Sustainability is reported with quantified operational inputs and emissions figures. PHOENIX reports 96,588 tonnes of CO₂e from capital goods in 2023/24.

Sustainability in the pharmaceutical wholesale industry

  • 1,300 U.S. corporate customers were served through MWI Animal Health’s reusable tote program, which nearly eliminated single-use cardboard and Styrofoam in 2024.[19]
  • 25 PHOENIX subsidiaries had digital-signature solutions in 2023/24, supporting paper reduction in administrative and distribution processes.[42]
  • 44% of Pharmacycle’s 2024 emissions came from purchased electricity used at its recycling facilities and operations.[43]
  • 54.6% is Cencora’s FY2032 target for reducing Scope 1 and 2 emissions, supported by hybrid and electric vehicles and photovoltaic installations.[19]
  • 31% of Pharmacycle’s 2024 emissions came from upstream transportation collecting blister packs from pharmacies across Australia.[43]

ESG in the pharmaceutical wholesale industry

  • 12 companies signed multi-buyer renewable-power purchase agreements through Energize, representing more than 800 GWh of annual renewable electricity.[44]
  • 70% of the pharmaceutical industry was represented by PSCI members in 2025, according to the initiative’s annual report.[44]
  • 1,505 third-party audit providers were engaged through PSCI activities in 2025.[44]
  • 900 suppliers received targeted renewable-electricity education and guidance through the PSCI-supported Energize program in 2025.[44]
  • 85 pharmaceutical and healthcare companies were PSCI members worldwide in 2025, comprising 39 full members and 46 associate members.[44]

Ethics in the pharmaceutical wholesale industry

  • 1% of 2,046 PSCI audit findings uploaded in 2024 concerned ethics in pharmaceutical and healthcare supply chains.[44]
  • 26 ethics-related findings were identified in PSCI’s analysis of 2,046 pharmaceutical and healthcare supplier-audit findings from 2024.[44]
  • 7 ethics-related findings were recorded in PSCI’s analysis of 1,776 supplier-audit findings from 2023.[44]

Circular economy in the pharmaceutical wholesale industry

  • 1,300 U.S. corporate customers were covered by MWI Animal Health’s reusable tote program, nearly eliminating single-use cardboard and Styrofoam in 2024.[19]
  • 30.7 million blister packs were processed for recycling by Pharmacycle in Australia during 2024.[43]
  • 17% of Pharmacycle’s 2024 emissions came from purchased goods and services supporting its pharmaceutical-packaging recycling operations.[43]

Carbon footprint in the pharmaceutical wholesale industry

  • 96,588 tonnes of CO₂e came from PHOENIX’s capital goods in 2023/24.[42]
  • 40,269 tonnes of CO₂e came from PHOENIX employee commuting in 2023/24.[42]
  • 24,712,913 tonnes of CO₂e were attributed to PHOENIX’s Scope 3 purchased goods and services in 2023/24.[42]
  • 110,933 tonnes of CO₂e came from PHOENIX’s upstream transport and distribution in 2023/24.[42]
  • 301 tonnes of CO₂e were Redcare Pharmacy’s Scope 1 emissions in 2024.[45]

15 Statistics

Globalization & Expansion

The footprint is expressed through counts of authorisations and logistics sites. PHOENIX operates 204 pharmaceutical wholesale and pre-wholesale sites in 29 countries.

Globalization in the pharmaceutical wholesale industry

  • 2,413 wholesale authorisations had been issued in Germany in 2021, according to data cited by the OECD.[58]
  • 421 wholesale authorisations had been issued in Poland in 2021, according to data cited by the OECD.[58]
  • €1.414 trillion was the estimated value of the global prescription pharmaceutical market at ex-factory prices in 2024.[59]
  • 29 European countries are served by PHOENIX Group’s pharmaceutical wholesale and pre-wholesale operations in fiscal 2024/25.[42]
  • 33,500 wholesale distributors and third-party logistics providers operated in the United States in 2023, according to the OECD’s review of medicine supply chains.[58]

Cultural adaptation in the pharmaceutical wholesale industry

  • 15 European countries contained PHOENIX Group-owned pharmacies operating under locally established retail brands.[42]
  • 182 independent pharmacies participated in OCP Portugal’s Farmacias Holon cooperation network.[42]
  • Over 18,000 pharmacies participated in PHOENIX Group cooperation and partnership programmes across Europe.[42]
  • More than 3,200 pharmacies were operated by PHOENIX Group in 15 European countries.[42]
  • 12 distribution centres supported PHOENIX Medical Supplies’ wholesale and pharmacy operations in the United Kingdom.[42]

Supplier management in the pharmaceutical wholesale industry

  • 95% of primary U.S. pharmaceutical distribution was handled by the 39 HDA members cited in 2024 industry reporting.[60]
  • Over 1,500 suppliers supplied the 39 HDA members responsible for 95% of primary U.S. pharmaceutical distribution, according to Pharmaceutical Commerce.[60]
  • $2 million was invested by Cardinal Health in 28 fiscal-2025 energy-efficiency projects involving its operational network.[16]
  • 2,000 or more suppliers supported McKesson Medical-Surgical’s distribution business.[61]
  • 28 energy-efficiency projects were deployed by Cardinal Health across its portfolio in fiscal 2025 while working with supply-chain partners.[16]

Stakeholder management in the pharmaceutical wholesale industry

  • 204 wholesale and pre-wholesale sites supplied pharmacies, doctors and medical institutions through PHOENIX Group’s network.[42]
  • More than 200,000 healthcare customers were served by McKesson Medical-Surgical.[61]
  • 1.25 million delivery-driving hours were performed annually by McKesson Medical-Surgical’s fleet.[61]
  • 95% of U.S. locations had next-day delivery available through McKesson Medical-Surgical’s distribution network.[61]
  • More than 48,000 employees worked across PHOENIX Group’s European healthcare businesses in fiscal 2024/25.[42]

Distribution channels in the pharmaceutical wholesale industry

  • 10.5% was the average European state share through VAT and other taxes in a medicine’s retail price in 2023.[59]
  • 20.4% of U.S. pharmaceutical distribution industry sales went to hospitals, health maintenance organisations and clinics in 2024.[1]
  • 7% of pharmaceutical products in the European Union were delivered directly from manufacturers to retail pharmacies in 2021.[58]
  • 17.5% was the average European pharmacist share of a medicine’s retail price in 2023.[59]
  • 6% of pharmaceutical products in the European Union were delivered through wholesalers to hospitals in 2021.[58]

Key questions about the pharmaceutical wholesale industry

What is the size of U.S. traditional pharmaceutical distributor sales?
U.S. traditional pharmaceutical distributor sales reached $969 billion in 2025.
How fast is the pharmaceuticals wholesale and distribution market expected to grow globally?
The global market is forecast to expand by approximately $1.097 trillion from 2025 to 2030, at a 9.7% CAGR.
Which companies lead the pharmaceutical wholesale industry?
McKesson leads Gitnux's 2026 pharmaceutical wholesale ranking with an Overall score of 9.5, with revenue growth 16.2% and operating margin 1.2%. Cencora is the runner-up at 9.2, with revenue growth 9.3% and operating margin 0.8%.
What technology shifts show up in distributor operations and planning?
Survey results show 76% of respondents expect AI can address returns and waste, and 50% of invoice lines were picked through automated processes in 2024.
How concentrated is the U.S. wholesale market and who dominates it?
The U.S. wholesale market is highly concentrated, with the top three wholesalers accounting for 85% combined in 2024 for Pfizer gross revenue shares.
What margin pressure do distributors face despite large sales volumes?
The HDA Research Foundation reported a 0.48% net profit margin for traditional pharmaceutical distributors in 2025.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 10). Pharmaceutical Wholesale Industry Statistics. Gitnux. https://gitnux.org/pharmaceutical-wholesale-industry-statistics
MLA
Samuel Norberg. "Pharmaceutical Wholesale Industry Statistics." Gitnux, 10 Nov 2026, https://gitnux.org/pharmaceutical-wholesale-industry-statistics.
Chicago
Samuel Norberg. 2026. "Pharmaceutical Wholesale Industry Statistics." Gitnux. https://gitnux.org/pharmaceutical-wholesale-industry-statistics.

Sources & references

73 sources cited across this report

  1. hda.org
  2. miebach.com
  3. ec.europa.eu
  4. databricks.com
  5. 44417324.fs1.hubspotusercontent-na1.net
  6. downloads.ctfassets.net
  7. cencora.com
  8. eco-cdn.iqpc.com
  9. informatica.com
  10. assets.contentstack.io
  11. mckesson.com
  12. ebs.publicnow.com
  13. drugchannelsinstitute.com
  14. investor.cencora.com
  15. ir.cardinalhealth.com
  16. newsroom.cardinalhealth.com
  17. investor.mckesson.com
  18. walgreensbootsalliance.com
  19. esg.cencora.com
  20. fred.stlouisfed.org
  21. cipd.org
  22. newsroom.cisco.com
  23. chemskills.eu
  24. deloitte.com
  25. seramount.com
  26. girp.eu
  27. b2bgrowth.eu
  28. spiegel.medill.northwestern.edu
  29. amerisourcebergen.com
  30. cardinalhealth.ca
  31. pure.itg.be
  32. radial.com
  33. cdn.asp.events
  34. mckinsey.com
  35. aspe.hhs.gov
  36. academic.oup.com
  37. ncbi.nlm.nih.gov
  38. syntaxpartners.com
  39. content-archive.fast-edgar.com
  40. inmar.com
  41. commonwealthfund.org
  42. phoenixgroup.eu
  43. pharmacycle.com.au
  44. pscinitiative.org
  45. csrd.bwdstrategic.com
  46. kpmg.com
  47. justice.gov
  48. oshacitations.com
  49. wtwco.com
  50. fluentcommerce.com
  51. sophos.com
  52. levelblue.com
  53. gov.uk
  54. cpl.thalesgroup.com
  55. iab.com
  56. hypr.com
  57. sec.gov
  58. oecd.org
  59. lif.dk
  60. pharmaceuticalcommerce.com
  61. mms.mckesson.com
  62. technavio.com
  63. sebi.gov.in
  64. fda.gov
  65. careers.mckesson.com
  66. zuelligpharma.com
  67. dksh.com
  68. en.sinopharm.com
  69. alfresa.com
  70. financialfilings.com
  71. tohohd.co.jp
  72. ashp.org
  73. cms.gov